PanFlu™
Influenza Prophylaxis
Phase 1Active
Key Facts
About Leyden Labs
Leyden Labs is pioneering a novel approach to respiratory virus protection by developing intranasal antibody sprays designed to provide immediate, broad-spectrum defense at the site of infection. The company's technology platform is built on two pillars: harnessing mucosal immunity for localized delivery and targeting conserved viral epitopes for enduring protection across virus families. Its lead program, PanFlu™, is in clinical development, with a pipeline aimed at creating self-administered products for both endemic and pandemic preparedness. Backed by a seasoned leadership team and strong investor syndicate, Leyden Labs is positioning itself as a key player in the next generation of antiviral prophylactics.
View full company profile